Cell Reports, Volume 39

Supplemental information

Antibodies targeting conserved non-canonical

antigens and endemic coronaviruses associate

with favorable outcomes in severe COVID-19

Sai Preetham Peddireddy, Syed A. Rahman, Anthony R. Cillo, Godhev Manakkat Vijay, Ashwin Somasundaram, Creg J. Workman, William Bain, Bryan J. McVerry, Barbara Methe, Janet S. Lee, Prabir Ray, Anuradha Ray, Tullia C. Bruno, Dario A.A. Vignali, Georgios D. Kitsios, Alison Morris, Harinder Singh, Aniruddh Sarkar, and Jishnu Das



Supplementary Figure 1 – Related to Figure 1.

A-O. Dot plots showing deep humoral profiles against canonical (S/RBD/N) Ag specificities for survivors, non-survivors, and healthy controls (A-IgG, B-IgG1, C-IgG3, D-IgA, E-IgA1, F-IgA2, G-IgM, H-Galactose, I-Sialic acid, J-FcR2a, K-FcR3a, L-FcR3b, M-FcR1, N-FcR2b, O-C1Q.

P. Correlation heatmap showing all corresponding pairwise feature correlations (Spearman) across non-survivors and survivors.

Q-S. Performance of LASSO model (precision, recall, F1 score respectively) to discriminate between survivors and non-survivors built using deep humoral profiles against canonical Ag specificities. Model performance is measured in a k-fold cross-validation framework with permutation testing. Actual denotes the performance of the model, built on real data. Permuted denotes performance of the model on shuffled data in a matched cross-validation framework (negative control).

T. Frequency of the 3 LASSO-selected featured and 3 random features across folds and replicates of k-fold cross-validation.

U. Dot-plots showing distributions of the 3 LASSO-selected features in 5 non-COVID-19 ARDS subjects (1 non-survivor, 4 survivors).

V. IgA.Spike and IgA2.Spike.RBD in survivors and non-survivors











Supplementary Figure 2 – Related to Figure 2.

A-O. Dot plots showing deep humoral profiles against non-canonical (orf3a/orf8/nsp3/nsp13/M) Ag specificities for survivors, non-survivors, and healthy controls (A-IgG, B-IgG1, C-IgG3, D-IgA, E-IgA1, F-IgA2, G-IgM, H-Galactose, I-Sialic acid, J-FcR2a, K-FcR3a, L-FcR3b, M-FcR1, N-FcR2b, O-C1Q.

P. Correlation heatmap showing all corresponding pairwise feature correlations (Spearman) across non-survivors and survivors.

Q-S. Performance of LASSO model (precision, recall, F1 score respectively) to discriminate between survivors and non-survivors built using deep humoral profiles against non-canonical Ag specificities. Model performance is measured in a k-fold cross-validation framework with permutation testing. Actual denotes the performance of the model, built on real data. Permuted denotes performance of the model on shuffled data in a matched cross-validation framework (negative control).

T. Frequency of the 4 LASSO-selected featured and 4 random features across folds and replicates of k-fold cross-validation.

U. Dot-plots showing distributions of the 4 LASSO-selected features in 5 non-COVID-19 ARDS subjects (1 non-survivor, 4 survivors).

V. LASSO-selected features from model built using deep humoral profiles against canonical and non-canonical Ag specificities.



OC43 S NL63 S Flu HA Ebola GP









Supplementary Figure 3 – Related to Figure 3.

A-O. Dot plots showing deep humoral profiles against non-SARS-CoV2 (HCoVOC43, HCoVNL63) Ag specificities for survivors, non-survivors, and healthy controls (A-IgG, B-IgG1, C-IgG3, D-IgA, E-IgA1, F-IgA2, G-IgM, H-Galactose, I-Sialic acid, J-FcR2a, K-FcR3a, L-FcR3b, M-FcR1, N-FcR2b, O-C1Q.

P. Correlation heatmap showing all corresponding pairwise feature correlations (Spearman) across non-survivors and survivors.

Q-S. Performance of LASSO model (precision, recall, F1 score respectively) to discriminate between survivors, non-survivors and healthy controls built using deep humoral profiles against canonical and non-canonical Ag specificities. Model performance (3-way) is measured in a k-fold cross-validation framework with permutation testing. Actual denotes the performance of the model, built on real data. Permuted denotes performance of the model on shuffled data in a matched cross-validation framework (negative control).

T-V. Performance of LASSO model (precision, recall, F1 score respectively) to discriminate between survivors, non-survivors and healthy controls built using deep humoral profiles against non-SARS-CoV2 Ag specificities. Model performance is measured in a k-fold cross-validation framework with permutation testing for outcome prediction between survivors, non-survivors, and healthy controls (3-way). Actual denotes the performance of the model, built on real data. Permuted denotes performance of the model on shuffled data in a matched cross-validation framework (negative control).